Affinage

IMP3

Signal peptide peptidase-like 2A · UniProt Q8TCT8

Audit flag: wrong gene
Length
520 aa
Mass
58.1 kDa
Annotated
2026-06-10
100 papers in source corpus 26 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IMP3 (IGF2BP3) is a multidomain RNA-binding protein that post-transcriptionally controls the fate of specific target mRNAs to drive cell proliferation, migration, and tumor-associated programs (PMID:15753088, PMID:23812426, PMID:25982283). It engages targets through a combinatorial recognition code in which all six RNA-binding domains (four KH and two RRM) contact clustered CA-rich and GGC-core elements spaced across a >100-nucleotide region (PMID:31118463); structurally, only RRM1 of the tandem RRM12 module contacts RNA in a uniquely oriented arrangement (PMID:30135093). Mechanistically IMP3 operates at multiple levels: it acts as a translational activator, enhancing translation of IGF-II via its 5' UTR and of p65/RELA mRNA via increased polysome association (PMID:15753088, PMID:21757716, PMID:28465487); it stabilizes target mRNAs by sequestering them in cytoplasmic RNP granules depleted of the Ago/miRNA machinery, protecting let-7 targets such as HMGA2 and LIN28B from miRNA-directed decay (PMID:24703842); and it destabilizes select transcripts, including ULBP2 to impair NK-cell recognition and PR mRNA via recruitment of the CCR4-NOT/CNOT1 deadenylase complex (PMID:26982091, PMID:29217458). In the nucleus, where its localization depends on the partner HNRNPM, IMP3 binds and is required for expression of cyclin D1, D3, and G1 mRNAs, protecting cyclin D mRNAs from AGO2/GW182-mediated translational repression together with ILF3/NF90 and PTBP1 (PMID:23812426, PMID:27840950). Through these activities IMP3 promotes cancer stem-cell self-renewal via a SLUG/SNAI2-SOX2 axis and TAZ/WNT5B signaling (PMID:25982283, PMID:29847788, PMID:25031719), chemoresistance via BCRP/ABCG2 and COX-2 mRNA stabilization (PMID:23539627, PMID:26342105), and migration/invasion via NF-κB, RhoA, and MEKK1/ERK signaling (PMID:34154626, PMID:25886367, PMID:25919292), with upstream induction by EGFR/MAPK signaling and repression by ERβ (PMID:22266872). Separately, in ribosome biogenesis IMP3 (as part of the Mpp10-Imp3-Imp4 complex) unfolds conserved stem structures in U3 snoRNA and pre-rRNA 18S helix 1 to promote U3-18S duplex formation required for small-subunit processome cleavage (PMID:23980203, PMID:30773582).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2005 High

    Established IMP3 as a sequence-specific translational activator rather than a transcriptional regulator, defining its core post-transcriptional mode of action on IGF-II mRNA.

    Evidence mRNP immunoprecipitation, siRNA knockdown, and chimeric leader-3/luciferase reporter in K562 cells

    PMID:15753088

    Open questions at the time
    • Did not map the RNA element or domains required for binding
    • Limited to IGF-II among possible targets
  2. 2011 High

    Connected IMP3-driven IGF-II translation to a physiological survival outcome, showing IMP3 promotes survival after ionizing radiation through 5' UTR-dependent IGF-II translation.

    Evidence 5' UTR reporter constructs, siRNA knockdown, and recombinant IGF-II rescue in an IR-apoptosis model

    PMID:21757716

    Open questions at the time
    • Mechanism by which IMP3 enhances 5' UTR translation not resolved
    • Single cell-line context
  3. 2012 High

    Defined upstream control of IMP3, showing it is induced by EGFR/MAPK signaling and repressed by ERβ, embedding IMP3 in oncogenic signaling networks.

    Evidence Promoter reporter assays, RNA-IP, siRNA/overexpression, and migration/invasion assays

    PMID:22266872

    Open questions at the time
    • Direct transcription factor binding to the IMP3 promoter not fully mapped
    • CD164/MMP9 regulation mechanism not detailed
  4. 2013 High

    Extended IMP3 targets to drug-resistance and cell-cycle machinery: it binds BCRP/ABCG2 mRNA to confer chemoresistance and is nuclear-enriched where it is required for cyclin D1/D3/G1 expression and G1 progression.

    Evidence RNA-IP, drug sensitivity assays, subcellular fractionation, and cell cycle analysis across multiple cancer lines; nuclear localization shown to depend on HNRNPM

    PMID:23539627 PMID:23812426

    Open questions at the time
    • How HNRNPM directs IMP3 nuclear import mechanistically unresolved
    • Whether cyclin regulation is at stability or translation not distinguished here
  5. 2014 High

    Revealed a stabilization mechanism distinct from translational activation: IMP3 granules act as 'safe houses' that exclude the miRNA/Ago machinery to protect let-7 target mRNAs from decay.

    Evidence Transcriptome analysis, cytoplasmic granule fractionation, antagomiR experiments, and HMGA2 3' UTR deletion constructs; plus RNA-IP/EMT rescue defining SLUG as a downstream target

    PMID:24703842 PMID:25031719

    Open questions at the time
    • What nucleates IMP3 granule assembly is unknown
    • How granules physically exclude Ago not defined
  6. 2015 Medium

    Linked IMP3 to stem-cell self-renewal and stress responses, defining a SLUG-SOX2 axis for breast cancer stem cells and stress-granule co-localization with LIN28/RELB partners.

    Evidence RNA-IP, 5' UTR reporters, xenograft tumor-initiation assays; co-IP and stress-granule immunofluorescence; NF-κB inhibition and migration assays in RCC; IL-18-induced IMP3-HuR/COX-2 stabilization in AML

    PMID:25794352 PMID:25886367 PMID:25919292 PMID:25982283 PMID:26342105

    Open questions at the time
    • Several mechanisms rest on single-lab co-IP or inhibitor epistasis
    • Direct versus indirect target distinctions not always established
  7. 2016 Medium

    Diversified the regulatory repertoire to include mRNA destabilization and partner-assisted control: IMP3 destabilizes ULBP2 to evade NK cells, protects cyclin D mRNAs with ILF3/PTBP1, and assembles defined circRNP complexes.

    Evidence RNA-IP, mRNA stability and NK cytotoxicity assays; polysome fractionation and co-IP; glycerol-gradient/RNA-seq circRNP characterization

    PMID:26982091 PMID:27510448 PMID:27840950

    Open questions at the time
    • Determinants of stabilize-versus-destabilize outcome unknown
    • Functional role of IMP3-bound circRNAs unresolved
  8. 2017 Medium

    Showed IMP3 drives migration through reinforcing feedback loops: it enhances p65/RELA translation in a positive loop with NF-κB, and cooperates with IMP2 to destabilize PR mRNA via CCR4-NOT.

    Evidence UV crosslinking, mutant 3' UTR reporters, polysome profiling, and rescue for p65; co-IP with CNOT1 and stability assays for PR

    PMID:28465487 PMID:29217458

    Open questions at the time
    • CNOT1 recruitment mechanism by IMP3 not structurally defined
    • p65 loop validated mainly in glioma context
  9. 2018 High

    Provided the molecular and structural basis for IMP3 specificity, defining a six-domain combinatorial recognition code and a unique tandem-RRM architecture.

    Evidence Single-domain SELEX-seq, iCLIP, motif-spacing analysis, and crystallography of RRM12

    PMID:30135093 PMID:31118463

    Open questions at the time
    • Full-length six-domain RNP structure on a native target not solved
    • How recognition code dictates stabilize-vs-destabilize fate not addressed
  10. 2020 Medium

    Expanded IMP3 targets into metabolic and signaling regulators and showed its activity is itself tunable by circRNA sponging.

    Evidence RNA pull-down, RIP, actinomycin-D stability assays, and binding-site mutagenesis for HK2/circCDKN2B-AS1; IP-ubiquitination and SMURF1 rescue for the PTEN-PI3K/AKT axis

    PMID:32938489 PMID:33308298

    Open questions at the time
    • Single-lab validation of each axis
    • Generality of circRNA sponging of IMP3 unknown
  11. 2021 High

    Provided in vivo genetic confirmation of IMP3-driven tumorigenesis through MEKK1/ERK signaling in colorectal cancer.

    Evidence RNA-IP, 3' UTR luciferase reporter, RNA-seq, and conditional IMP3 knockout in an AOM/DSS mouse model

    PMID:34154626

    Open questions at the time
    • Tissue specificity of MEKK1 stabilization not explored
    • Relationship to other IMP3 migration pathways not integrated
  12. 2013 High

    Defined a mechanistically separate, conserved role for Imp3 in ribosome biogenesis as an RNA-structure chaperone unfolding U3 snoRNA and pre-rRNA stems to enable processome cleavage.

    Evidence Chemical modification probing, ribonuclease accessibility, and in vitro reconstitution of U3-18S hybridization in yeast/zebrafish; zebrafish genetics defining Sas10/Def-dependent nucleolar localization and Mpp10 stability

    PMID:23980203 PMID:30773582

    Open questions at the time
    • Whether this processome role exists in human cells alongside mRNA functions not addressed in this corpus
    • How the same protein partitions between nucleolar and cytoplasmic mRNA roles unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved what molecular features of a bound transcript determine whether IMP3 stabilizes, destabilizes, or translationally activates it, and how IMP3 partitions between its mRNA-regulatory and ribosome-biogenesis functions.
  • No unifying rule linking RNA recognition code to regulatory outcome
  • No structure of full-length IMP3 on a native target
  • Crosstalk between processome and mRNA roles uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 6 GO:0045182 translation regulator activity 4 GO:0060090 molecular adaptor activity 3 GO:0140098 catalytic activity, acting on RNA 1
Localization
GO:0005829 cytosol 2 GO:0005634 nucleus 1 GO:0005730 nucleolus 1
Pathway
R-HSA-1643685 Disease 4 R-HSA-8953854 Metabolism of RNA 4 R-HSA-162582 Signal Transduction 3 R-HSA-1852241 Organelle biogenesis and maintenance 2 R-HSA-1640170 Cell Cycle 1
Partners
CNOT1HNRNPMHURILF3IMP2LIN28APTBP1RELB
Complex memberships
IMP3-HuR complexMpp10-Imp3-Imp4 complex

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 IMP3 associates with IGF-II leader-3 and leader-4 mRNAs and H19 RNA (but not c-myc or beta-actin mRNAs) in vivo, and acts as a translational activator of IGF-II leader-3 mRNA; IMP3 knockdown reduced IGF-II protein levels without affecting mRNA levels and specifically suppressed translation of a chimeric IGF-II leader-3/luciferase reporter, demonstrating post-transcriptional translational activation. mRNP immunoprecipitation, siRNA knockdown, chimeric luciferase reporter assay in K562 cells The Journal of biological chemistry High 15753088
2011 IMP3 promotes cell survival after ionizing radiation by acting through the 5' UTR of IGF-II mRNA to enhance its translation; IMP3 knockdown increased IR-induced apoptosis and reduced IGF-II production, and exogenous recombinant IGF-II partially reversed these effects. siRNA knockdown, gene reporter assays with 5' UTR constructs, IR-induced apoptosis model in K562 cells The Journal of biological chemistry High 21757716
2012 IMP3 expression is induced transcriptionally by EGFR signaling via the MAPK pathway, and is repressed specifically by estrogen receptor β (ERβ) and its ligand 3βA-diol (but not ERα); ERβ also represses EGFR transcription via an imperfect estrogen response element in the EGFR promoter, providing an indirect mechanism for ERβ to suppress IMP3. IMP3 was shown to bind CD164 and MMP9 mRNAs, contributing to migration and invasion. siRNA/overexpression, promoter reporter assays, RNA immunoprecipitation, migration/invasion assays Oncogene High 22266872
2013 IMP3 binds BCRP (ABCG2) mRNA and regulates BCRP protein expression; depletion of IMP3 in triple-negative breast cancer cells increased sensitivity to doxorubicin and mitoxantrone (substrates of BCRP) but not taxol, establishing IMP3 as a regulator of chemoresistance through BCRP mRNA binding. siRNA knockdown, RNA immunoprecipitation, drug sensitivity assays The Journal of biological chemistry High 23539627
2013 IMP3 is enriched in the nucleus of human cancer cells (compared to IMP1 and IMP2), where it binds CCND1, CCND3, and CCNG1 mRNAs and is required for their expression; IMP3 knockdown caused dramatic loss of cyclins D1, D3, and G1 protein and G1 cell cycle arrest. Nuclear localization depends on the protein partner HNRNPM, and cytoplasmic retention of IMP3 abolishes cyclin regulation. siRNA knockdown, in vivo and in vitro RNA binding assays, subcellular fractionation, cell cycle analysis across six cancer cell lines Oncogene High 23812426
2014 IMP3 ribonucleoprotein granules function as cytoplasmic 'safe houses' that protect let-7 target mRNAs (including HMGA2 and LIN28B) from miRNA-directed decay; IMP3-containing bodies are depleted of Ago1-4 and miRNAs, and IMP3 dose-dependently increases HMGA2 mRNA. Removal of let-7 target sites or let-7 antagomiRs abolishes IMP3-dependent stabilization. Transcriptome analysis, cytoplasmic granule fractionation, antagomiR experiments, HMGA2 3' UTR deletion constructs Cell reports High 24703842
2015 IMP3 binds SNAI2 (SLUG) mRNA at the 5' UTR and regulates SLUG expression; SLUG in turn transcriptionally activates SOX2, promoting breast cancer stem cell self-renewal and tumor initiation in triple-negative breast cancer. IMP3 does not bind SOX2 mRNA directly. RNA immunoprecipitation, 5' UTR reporter assays, siRNA/overexpression, tumor initiation assays in xenograft models Oncogene High 25982283
2016 IMP3 directly interacts with ULBP2 mRNA, leading to its destabilization and reduced ULBP2 surface expression in human cell lines, thereby impairing NK cell recognition. IMP3 also indirectly targets MICB through a mechanistically distinct pathway. RNA immunoprecipitation, mRNA stability assays, NK cell cytotoxicity assays, flow cytometry for surface expression eLife High 26982091
2016 IMP3 and its partners ILF3/NF90 and PTBP1 bind to the 3' UTRs of cyclin D1 and D3 mRNAs and protect them from translational repression induced by AGO2/GW182-dependent miRNA pathway; upon IMP3 knockdown, cyclin mRNAs remain polysome-associated but are not translated, indicating regulation at the translational level. siRNA knockdown, polysome fractionation, 3' UTR binding assays, co-immunoprecipitation International journal of oncology Medium 27840950
2016 IMP3 forms circRNA-protein complexes (circRNPs) with a defined subset of circular RNAs in mammalian cells; glycerol gradient centrifugation revealed circRNPs of distinct sizes, and RNA-seq of IMP3-co-immunoprecipitated RNA identified specific IMP3-associated circRNAs. No evidence was found for efficient translation of these abundant circRNAs. Glycerol gradient centrifugation, co-immunoprecipitation of RNA, polysome gradient fractionation, RNA-seq Scientific reports Medium 27510448
2017 IMP3 promotes glioma cell migration by directly binding p65 (RELA) mRNA 3' UTR and enhancing its translation (polysome association increased without change in transcript level); exogenous p65 from a 3'UTR-less construct rescued migration in IMP3-silenced cells. A positive feedback loop exists between IMP3 and NF-κB/p65, as IMP3 is transcriptionally activated by NF-κB. RNA immunoprecipitation-PCR, UV crosslinking with in vitro transcribed RNA, 3'UTR luciferase reporter (wild-type vs. mutant), polysome profiling, migration assays Oncotarget High 28465487
2017 IMP2 and IMP3 cooperate to promote TNBC metastasis by destabilizing progesterone receptor (PR) mRNA through recruitment of the CCR4-NOT/CNOT1 complex, suppressing PR expression and thereby downregulating miR-200a; this forms a double-negative feedback loop. siRNA knockdown/overexpression, co-immunoprecipitation with CNOT1, mRNA stability assays, migration/invasion assays Cancer letters Medium 29217458
2018 Crystal structure of IMP3 RRM12 reveals that both RRM domains adopt canonical RRM topology; only RRM1 contacts RNA and recognizes a dinucleotide sequence; the spatial orientation of RRM1 relative to RRM2 is unique compared to other tandem RRM structures. X-ray crystallography, biochemical RNA binding characterization RNA (New York, N.Y.) High 30135093
2018 IMP3 stabilizes WNT5B mRNA indirectly by repressing miR-145-5p (which targets WNT5B), leading to TAZ activation via alternative WNT signaling. IMP3 also facilitates SLUG transcription (required for TAZ nuclear localization) through a WNT5B-dependent mechanism, integrating Hippo and alternative WNT signaling pathways. mRNA stability assays, miRNA manipulation, siRNA/overexpression, reporter assays, breast cancer stem cell functional assays Cell reports Medium 29847788
2019 IMP3 uses a combinatorial RNA recognition code involving all six RNA-binding domains (four KH and two RRM) to recognize a cluster of up to five distinct CA-rich and GGC-core RNA elements appropriately spaced across a >100 nucleotide target region; single-domain SELEX-seq, iCLIP, structural biology, and functional validation together define the RNA-binding specificity and RNP topology. Single-domain SELEX-seq, iCLIP, motif-spacing analysis, structural biology, functional reporter assays Nature communications High 31118463
2015 IL-18 signaling induces shuttling of IMP3 and HuR from nucleus to cytoplasm and facilitates their interaction; the IMP3-HuR complex then binds the 3' UTR of COX-2 mRNA to stabilize it, contributing to chemoresistance in AML cells. JNK and/or ERK1/2 regulate HuR nucleocytoplasmic shuttling in this pathway. Co-immunoprecipitation, RNA immunoprecipitation, subcellular fractionation, mRNA stability assays Journal of leukocyte biology Medium 26342105
2015 RELB interacts with IMP3 and LIN28A in human pluripotent stem cells; these interactions control mRNA levels and protein expression of IGF2 and key cell-cycle genes; after stress, IMP3, LIN28, and RELB co-localize in stress granules. Co-immunoprecipitation, stress granule co-localization (immunofluorescence), quantitative PCR and western blot Stem cells and development Medium 25794352
2020 IMP3 directly binds the 3' UTR of HK2 mRNA (hexokinase 2) to stabilize it; circCDKN2B-AS1 acts as a sponge for IMP3 protein, sequestering it and thereby modulating how much IMP3 is available to bind HK2 mRNA 3' UTR. Mutant circCDKN2B-AS1 lacking the IMP3 binding site lacks this effect. RNA pull-down, RNA immunoprecipitation, actinomycin-D mRNA stability assay, binding-site mutagenesis, western blot Journal of experimental & clinical cancer research : CR Medium 33308298
2020 IMP3 promotes prostate cancer progression by upregulating SMURF1 expression, which in turn facilitates PTEN ubiquitination and degradation, activating the PI3K/AKT/mTOR signaling pathway; SMURF1 knockdown rescues the proliferative and survival phenotypes induced by IMP3 overexpression. Immunoprecipitation/ubiquitination assay, siRNA/overexpression, western blot for PI3K/AKT/mTOR pathway components, in vivo tumor formation Journal of experimental & clinical cancer research : CR Medium 32938489
2021 IMP3 directly binds the 3' UTR of MEKK1 mRNA to stabilize it, promoting MEKK1 expression and sequentially activating MEK1/ERK signaling in colorectal cancer; IMP3 conditional knockout mice show decreased MEKK1 expression and reduced colorectal tumors in an AOM/DSS model. RNA immunoprecipitation, luciferase 3'UTR reporter assay, RNA-sequencing, conditional IMP3 knockout mouse, western blot Journal of experimental & clinical cancer research : CR High 34154626
2013 In yeast/zebrafish model: Imp3 (as part of the Mpp10-Imp3-Imp4 complex) unfolds both the box A/A' stem in U3 snoRNA and helix 1 (H1) in the 18S region of pre-rRNA to promote U3-18S duplex formation required for small subunit processome cleavages at A0 and A1 sites; Imp3 binding alone provides sufficient energy for this unfolding, while Imp4 destabilizes the duplex to aid U3 release. Chemical modification probing, ribonuclease accessibility assay, in vitro reconstitution of U3-18S hybridization RNA (New York, N.Y.) High 23980203
2019 In zebrafish model: Sas10 determines the nucleolar localization of the Mpp10-Imp3-Imp4 complex; Sas10 protects Mpp10 from Capn3-mediated cleavage by masking the Capn3-recognition site, while Def interacts with Sas10 to form the Def-Sas10-Mpp10 complex that facilitates Capn3-mediated Mpp10 cleavage. Mpp10, but not Sas10, is a target of the Def-Capn3 degradation pathway. Zebrafish genetics, co-immunoprecipitation, nucleolar localization studies, protein stability assays Nucleic acids research Medium 30773582
2014 IMP3 binds SLUG (SNAI2) mRNA directly (confirmed by ribo-immunoprecipitation qPCR) and regulates SLUG expression; IMP3 overexpression induces EMT markers (reduced E-cadherin, increased Slug and vimentin); knockdown of SLUG in IMP3-overexpressing cells reverses migration and invasion, and SLUG overexpression rescues invasion in IMP3-depleted cells, establishing SLUG as a functional downstream target of IMP3 in EMT. RNA immunoprecipitation-qPCR, siRNA knockdown/overexpression, Transwell migration/invasion assays, western blot for EMT markers International journal of clinical and experimental pathology Medium 25031719
2015 IMP3 knockdown in pancreatic ductal adenocarcinoma cells significantly decreased cell motility, invasion, and extracellular matrix adhesion; IMP3-depleted cells showed reduced CD44 protein levels, decreased KIF11 mRNA, and reduced downstream RhoA signaling, indicating IMP3 modulates cytoskeletal organization via RhoA pathway. siRNA knockdown, Transwell migration/invasion assay, matrix adhesion assay, western blot for RhoA pathway BMC cancer Medium 25886367
2015 IMP3 overexpression activates the NF-κB pathway in renal cell carcinoma cells, and pharmacological inhibition of NF-κB abrogates IMP3-promoted cell migration, placing IMP3 upstream of NF-κB in promoting RCC cell migration. Stable IMP3 overexpression, siRNA knockdown, RNA-seq, Transwell migration assay, NF-κB inhibition PloS one Medium 25919292
2024 IMP3 knockdown in HeLa cervical cancer cells significantly reduced cell migration without altering cell proliferation, demonstrating a specific role of IMP3 in cell motility regulation. siRNA knockdown, scratch/wound-healing migration assay, proliferation assay The American journal of surgical pathology Low 21997684

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. The Journal of biological chemistry 192 15753088
2010 Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 141 20562850
2016 CircRNA-protein complexes: IMP3 protein component defines subfamily of circRNPs. Scientific reports 130 27510448
2008 The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. The American journal of surgical pathology 121 18223334
2015 Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. British journal of cancer 102 26158423
2008 IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clinical cancer research : an official journal of the American Association for Cancer Research 97 18347170
2012 Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer. Oncogene 93 22266872
2009 IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Human pathology 84 19695680
2019 Combinatorial recognition of clustered RNA elements by the multidomain RNA-binding protein IMP3. Nature communications 82 31118463
2014 IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. Cell reports 80 24703842
2008 IMP-3 is a novel progression marker in malignant melanoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 72 18204432
2008 Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 71 18412154
2007 Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 68 17885673
2013 IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression. The Journal of biological chemistry 65 23539627
2008 Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research 64 18765551
2020 CircCDKN2B-AS1 interacts with IMP3 to stabilize hexokinase 2 mRNA and facilitate cervical squamous cell carcinoma aerobic glycolysis progression. Journal of experimental & clinical cancer research : CR 62 33308298
2015 IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG. Oncogene 62 25982283
2010 Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagnostic cytopathology 61 21574259
2017 IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. Cancer letters 59 29217458
2010 S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Human pathology 58 20382408
2011 Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. The American journal of surgical pathology 55 21566519
2009 An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. The American journal of surgical pathology 55 19047899
2017 IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncology reports 54 29115542
2011 RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation. The Journal of biological chemistry 53 21757716
2011 IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. The American journal of surgical pathology 53 21997684
2014 Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. American journal of clinical pathology 49 24343741
2013 Post-transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP-3 nuclear localization. Oncogene 47 23812426
2014 Oncofetal protein IMP3, a new cancer biomarker. Advances in anatomic pathology 46 24713990
2016 The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB. eLife 44 26982091
2013 IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. The American journal of surgical pathology 43 23108021
2011 Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. The American journal of surgical pathology 42 21566520
2009 IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Human pathology 40 19698973
2015 Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression. PloS one 38 25919292
2012 Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma. Human pathology 36 22497850
2018 IMP3 Stabilization of WNT5B mRNA Facilitates TAZ Activation in Breast Cancer. Cell reports 34 29847788
2013 ER+ /PR+ /TFF3+ /IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology 32 23570281
2012 Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology 32 22211286
2012 IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagnostic pathology 32 23190601
2020 IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way. Journal of experimental & clinical cancer research : CR 31 32938489
2009 IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Human pathology 30 20004948
2008 Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Human pathology 29 18547613
2019 Sas10 controls ribosome biogenesis by stabilizing Mpp10 and delivering the Mpp10-Imp3-Imp4 complex to nucleolus. Nucleic acids research 28 30773582
2009 Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocrine pathology 28 19449140
2018 Structural basis of IMP3 RRM12 recognition of RNA. RNA (New York, N.Y.) 27 30135093
2011 Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. Journal of surgical oncology 27 22012575
2010 Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC cancer 27 20591150
2017 IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65. Oncotarget 26 28465487
2014 IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma. Human pathology 26 24745619
2015 IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia. Journal of leukocyte biology 25 26342105
2009 IMP3 expression in human ovarian cancer is associated with improved survival. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 25 19620937
2008 Expression of insulin-like growth factor-II mRNA binding protein 3 (IMP3) in osteosarcoma. Oncology research 24 19192721
2017 Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasound-guided fine needle aspiration and resected specimens of pancreatic diseases. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 23 29305088
2012 Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder. Human pathology 23 23079206
2016 Laminin-5 and insulin-like growth factor-II mRNA binding protein-3 (IMP3) expression in preoperative biopsy specimens from oral cancer patients: Their role in neural spread risk and survival stratification. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 22 27863864
2014 IMP3 expression is associated with epithelial-mesenchymal transition in breast cancer. International journal of clinical and experimental pathology 22 25031719
2012 Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy. Applied immunohistochemistry & molecular morphology : AIMM 22 22495381
2012 Up-regulation of Imp3 confers in vivo tumorigenicity on murine osteosarcoma cells. PloS one 22 23226335
2009 IMP-3 expression in melanocytic lesions. Journal of cutaneous pathology 22 19788446
2015 The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. BMC cancer 21 25886367
2013 The oncofetal protein IMP3: a novel biomarker and triage tool for premalignant atypical endometriotic lesions. Fertility and sterility 21 23473990
2013 Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma. Journal of neuro-oncology 21 24135846
2011 The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis. Journal of molecular histology 21 22042095
2014 The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20 25144243
2014 IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status. Journal of cancer research and clinical oncology 20 25323937
2010 Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study. Diagnostic molecular pathology : the American journal of surgical pathology, part B 20 20502182
2018 IMP3 promotes TNBC stem cell property through miRNA-34a regulation. European review for medical and pharmacological sciences 19 29771420
2017 IMP3 expression in biopsy specimens as a diagnostic biomarker for colorectal cancer. Human pathology 19 28412210
2013 IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. European journal of histochemistry : EJH 19 23549465
2013 IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma. Human pathology 19 23845468
2015 Chromosome 12p abnormalities and IMP3 expression in prepubertal pure testicular teratomas. Human pathology 18 26826410
2021 RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA. Journal of experimental & clinical cancer research : CR 17 34154626
2015 IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage. International journal of clinical and experimental pathology 17 26617820
2021 Diagnostic value of IMP3 and p53 immunohistochemical staining in EUS-guided fine-needle aspiration for solid pancreatic tumors. Scientific reports 15 34446759
2018 Immunohistochemical staining for S100P, SMAD4, and IMP3 on cell block preparations is sensitive and highly specific for pancreatic ductal adenocarcinoma. Journal of the American Society of Cytopathology 15 31043302
2015 IMP3 Is Strongly Expressed in Malignant Phyllodes Tumors of the Breast: An Immunohistochemical Study. International journal of surgical pathology 15 26353850
2020 Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Pathology, research and practice 14 32273198
2018 Diagnostic Value of S100p, IMP3, Maspin, and pVHL in the Differantial Diagnosis of Pancreatic Ductal Adenocarcinoma and Normal/chronic Pancreatitis in Fine Needle Aspiration Biopsy. Journal of cytology 14 30498299
2016 Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis. Pathology, research and practice 14 26874572
2013 Imp3 unfolds stem structures in pre-rRNA and U3 snoRNA to form a duplex essential for small subunit processing. RNA (New York, N.Y.) 14 23980203
2017 IGF2 mRNA binding protein 3 (IMP3) mediated regulation of transcriptome and translatome in glioma cells. Cancer biology & therapy 13 28485999
2015 EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 13 26386725
2014 Expression and clinical significance of IMP3 in microdissected premalignant and malignant pancreatic lesions. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 13 25183049
2013 The utility of PAX8 and IMP3 immunohistochemical stains in the differential diagnosis of benign, premalignant, and malignant endocervical glandular lesions. Gynecologic oncology 13 23618832
2013 Oncofetal protein IMP3: a new diagnostic biomarker for laryngeal carcinoma. Human pathology 13 23806529
2012 IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver. Applied immunohistochemistry & molecular morphology : AIMM 13 22495359
2011 The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Archives of pathology & laboratory medicine 13 21809995
2023 Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma. Frontiers in oncology 12 36937398
2016 IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International journal of oncology 12 27840950
2020 IGF2BP3 (IMP3) expression in angiosarcoma, epithelioid hemangioendothelioma, and benign vascular lesions. Diagnostic pathology 11 32293476
2016 Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma. Pathology, research and practice 11 26948096
2023 Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components. Histopathology 10 37140546
2017 IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression. American journal of translational research 10 28804555
2016 The role of S100P and IMP3 in the cytologic diagnosis of pancreatic adenocarcinoma. Journal of the Egyptian National Cancer Institute 10 27839709
2015 The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas. BioMed research international 10 25695077
2015 Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 10 25740666
2015 RELB Alters Proliferation of Human Pluripotent Stem Cells via IMP3- and LIN28-Mediated Modulation of the Expression of IGF2 and Other Cell-Cycle Regulators. Stem cells and development 10 25794352
2014 IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis. Journal of experimental & clinical cancer research : CR 10 25038792
2010 Analysis of IMP3 expression in normal and neoplastic human pituitary tissues. Endocrine pathology 10 19898970
2021 IMP3 Protein Overexpression Is Linked to Unfavorable Outcome in Laryngeal Squamous Cell Carcinoma. Cancers 9 34503117
2014 Differential expression of IMP3 between male and female mature teratomas--immunohistochemical evidence of malignant nature. Histopathology 9 24605891

Missed literature

Know a paper Affinage missed for IMP3? Flag it for the maintainers and the community.

No submissions yet.